Arenaviruses Treatment & Management
- Author: Sandra G Gompf, MD, FACP, FIDSA; Chief Editor: Burke A Cunha, MD more...
Medical Care
No specific medical care is required for mild infections associated with any of the Arenaviridae. Specific and/or careful symptomatic care is needed in more severe infections associated with those agents linked to hemorrhagic fever.
LCM virus infection requires no more than symptomatic treatment.
In overt cases of Lassa fever or any of the South American hemorrhagic fevers, aggressive treatment is needed to attempt to diminish morbidity and mortality.
Supportive care related to blood pressure monitoring/control and careful attention to fluid and electrolytic balance can be lifesaving.
The antiviral drug ribavirin is used in Lassa fever and has also shown efficacy in cases of South American hemorrhagic fever.
Convalescent human plasma has been used with some success in the treatment of Junin virus infection. The lack of parallel success in Lassa fever may be related to low and delayed titers of the specific neutralizing antibody in Lassa fever.
Consultations
With a compatible illness and travel history, any individual in whom either Lassa fever or one of the South American hemorrhagic fevers is suggested should have immediate consultation with an infectious disease physician and the local public health authorities.
Bateman C. Arenavirus deaths--emergency air services tighten up. S Afr Med J. Dec 2008;98(12):910, 912, 914. [Medline].
Whitby LR, Lee AM, Kunz S, Oldstone MB, Boger DL. Characterization of lassa virus cell entry inhibitors: Determination of the active enantiomer by asymmetric synthesis. Bioorg Med Chem Lett. May 3 2009;[Medline].
Fichet-Calvet E, Rogers DJ. Risk maps of lassa Fever in west Africa. PLoS Negl Trop Dis. 2009;3(3):e388. [Medline].
Cosset FL, Marianneau P, Verney G, Gallais F, Tordo N, Pécheur EI, et al. Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles. J Virol. Apr 2009;83(7):3228-37. [Medline].
Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. Jun 2009;82(3):95-102. [Medline].
Banerjee C, Allen LJ, Salazar-Bravo J. Models for an arenavirus infection in a rodent population: consequences of horizontal, vertical and sexual transmission. Math Biosci Eng. Oct 2008;5(4):617-45. [Medline].
Biggar RJ, Woodall JP, Walter PD, Haughie GE. Lymphocytic choriomeningitis outbreak associated with pet hamsters. Fifty-seven cases from New York State. JAMA. May 5 1975;232(5):494-500. [Medline].
Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, et al. Genetic detection and characterization of lujo virus, a new hemorrhagic Fever-associated arenavirus from southern Africa. PLoS Pathog. May 2009;5(5):e1000455. [Medline].
Buchmeier MJ, et al. Arenaviridae: the viruses and their replication. In: Knipe DL, and Howley, PM. Field's Virology. 4. Philadelphia, PA: Lippencott-Raven; 2007:1791-1828.
Buckley SM, Casals J. Pathobiology of Lassa fever. Int Rev Exp Pathol. 1978;18:97-136. [Medline].
Cao W, Henry MD, Borrow P, et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science. Dec 11 1998;282(5396):2079-81. [Medline].
Centers for Disease Control and Prevention. Arenavirus infection--Connecticut, 1994. MMWR Morb Mortal Wkly Rep. Sep 2 1994;43(34):635-6. [Medline].
Centers for Disease Control and Prevention. Fatal illnesses associated with a new world arenavirus--California, 1999-2000. MMWR Morb Mortal Wkly Rep. Aug 11 2000;49(31):709-11. [Medline].
Charrel RN, Coutard B, Baronti C, et al. Arenaviruses and hantaviruses: From epidemiology and genomics to antivirals. Antiviral Res. May 2011;90(2):102-14. [Medline].
Cummins D, McCormick JB, Bennett D, et al. Acute sensorineural deafness in Lassa fever. JAMA. Oct 24-31 1990;264(16):2093-6. [Medline].
Delgado S, Erickson BR, Agudo R, et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. Apr 2008;4(4):e1000047. [Medline].
Fischer SA, Graham MB, Kuehnert MJ. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354:2208-11.
Hinman AR, Fraser DW, Douglas RG, et al. Outbreak of lymphocytic choriomeningitis virus infections in medical center personnel. Am J Epidemiol. Feb 1975;101(2):103-10. [Medline].
Holmes GP, McCormick JB, Trock SC. Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med. Oct 18 1990;323(16):1120-3. [Medline].
Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, et al. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature. Feb 20 1992;355(6362):696-702. [Medline].
Inegbenebor U, Okosun J, Inegbenebor J. Prevention of lassa Fever in Nigeria. Trans R Soc Trop Med Hyg. Jan 2010;104(1):51-4. [Medline].
Jay MT, Glaser C, Fulhorst CF. The arenaviruses. J Am Vet Med Assoc. 2005;227:904-15.
Khan SH, Goba A, Chu M, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. Apr 2008;78(1):103-15. [Medline].
Kiley MP, Lange JV, Johnson KM. Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet. Oct 6 1979;2(8145):738. [Medline].
Kunz S, de la Torre JC. Novel antiviral strategies to combat human Arenavirus infections. Curr Mol Med. 2005;5:735-51.
Lan S, McLay Schelde L, Wang J, Kumar N, Ly H, Liang Y. Development of infectious clones for virulent and avirulent Pichinde viruses - a model virus to study arenavirus-induced hemorrhagic fevers. J Virol. Apr 22 2009;[Medline].
Maiztegui JI. Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ. 1975;52(4-6):567-75. [Medline].
Maiztegui JI, McKee KT Jr, Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis. Feb 1998;177(2):277-83. [Medline].
McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. Jan 2 1986;314(1):20-6. [Medline].
Paweska JT, Sewlall NH, Ksiazek TG, et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis. Oct 2009;15(10):1598-602. [Medline]. [Full Text].
Peters CJ. Lymphocytic Choriomeningitis Virus, Lassa Virus, and the South American Hemorrhagic Fevers. In: Gerald L. Mandell, John E. Bennett, Raphael Dolin. Principles and Practice of Infectious Diseases. 2. 7. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:2295-2302.
Radoshitzky SR, Abraham J, Spiropoulou CF, et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature. Mar 1 2007;446(7131):92-6. [Medline].
Stinebaugh BJ, Schloeder FX, Johnson KM, et al. Bolivian hemorrhagic fever. A report of four cases. Am J Med. Feb 1966;40(2):217-30. [Medline].
Vanzee BE, Douglas RG, Betts RF, et al. Lymphocytic choriomeningitis in university hospital personnel. Clinical features. Am J Med. Jun 1975;58(6):803-9. [Medline].
Zweighaft RM, Fraser DW, Hattwick MA, et al. Lassa fever: response to an imported case. N Engl J Med. Oct 13 1977;297(15):803-7. [Medline].

